StocksMediumUpdated•Originally published 12 October 2026•Updated 12 October 2026•
1 min read
Mirum Pharmaceuticals Reports Success in Phase 3 LIVMARLI Study
Key Facts
1Mirum Pharmaceuticals announced that the primary endpoint was met in the Phase 3 EXPAND study of LIVMARLI.
Mirum Pharmaceuticals announced that the Phase 3 EXPAND study of LIVMARLI successfully met its primary endpoint. According to a statement via Business Wire, the results for maralixibat demonstrated significant reductions in itching and bile acids specifically in patients with biliary atresia.
This clinical milestone supports potential regulatory expansion for the treatment of these ultra-rare cholestatic liver diseases. MIRM was trading at $86.01 on October 9, 2026, within a session range of $81.01 to $87.79.